PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsHuman fibrinogen
Fibrinogen human
Evicel, TachoSil, VeraSeal (fibrinogen, human) is an unknown pharmaceutical. Fibrinogen, human was first approved as Tachosil on 2004-06-08. It is used to treat afibrinogenemia and hemorrhage in the USA. It has been approved in Europe to treat hemostasis and surgical hemostasis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
signs and symptoms pathological conditionsD013568
therapeuticsD013812
operative surgical proceduresD013514
circulatory and respiratory physiological phenomenaD002943
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
riastapBiologic Licensing Application2010-03-01
tachosilBiologic Licensing Application2025-02-11
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B02: Antihemorrhagics
— B02B: Vitamin k and other hemostatics
— B02BB: Fibrinogen containing hemostatics
— B02BB01: Fibrinogen, human
HCPCS
No data
Clinical
Clinical Trials
367 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HemorrhageD006470MP_0001914R5871713153176
Blood coagulation disordersD001778EFO_0009314D68.934383247
Hemostatic disordersD020141——34383247
AfibrinogenemiaD000347—D68.21694926
Wounds and injuriesD014947—T14.857221022
ThrombosisD013927————131014
Surgical blood lossD016063———241714
Heart diseasesD006331EFO_0003777I51.9—321612
Postpartum hemorrhageD006473—O72121248
HemostasisD006487——121227
Show 39 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.9—25—18
InflammationD007249MP_0001845———1—78
IschemiaD007511EFO_0000556——25—18
Ischemic strokeD000083242———25——7
Coronary artery diseaseD003324—I25.1—21—47
Cardiovascular diseasesD002318EFO_0000319I98—11—46
Myocardial ischemiaD017202EFO_1001375I20-I25——1—45
Postoperative hemorrhageD019106———11—35
UlcerD014456MPATH_579——13—15
AcromegalyD000172————1—34
Show 30 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382—U07.111——1517
InfectionsD007239EFO_0000544——1——34
Multiple traumaD009104—T0711——34
Aortic dissectionD000784—I71.0—1——34
Pituitary dwarfismD004393EFO_1001109E23.0—1——23
DwarfismD004392—E34.31—1——23
HyperinsulinismD006946—E16.1—1——23
Transfusion reactionD065227—D69.51—1——23
AtrophyD001284———1——23
GallstonesD042882EFO_0004210——1——12
Show 24 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C804———15
NeutropeniaD009503—D703————3
Chemotherapy-induced febrile neutropeniaD064146——3————3
Alzheimer diseaseD000544EFO_0000249F031———12
Insulin resistanceD007333EFO_0002614E88.8191———12
Gastrointestinal hemorrhageD006471—K92.21————1
GliomaD005910EFO_0000520—1————1
Brain stem neoplasmsD020295EFO_1001767—1————1
PinealomaD010871——1————1
Neoplasm metastasisD009362EFO_0009708—1————1
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EmbolismD004617——————66
Liver cirrhosisD008103EFO_0001422K74.0————66
FibrosisD005355——————66
Coagulation protein disordersD020147——————55
Pulmonary embolismD011655EFO_0003827I26————55
BurnsD002056—T30.0————44
Venous thromboembolismD054556EFO_0004286I74————44
Liver transplantationD016031EFO_0010682—————44
Coronary diseaseD003327——————44
LeukemiaD007938—C95————44
Show 163 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFibrinogen human
INN—
Description
Evicel, TachoSil, VeraSeal (fibrinogen, human) is an unknown pharmaceutical. Fibrinogen, human was first approved as Tachosil on 2004-06-08. It is used to treat afibrinogenemia and hemorrhage in the USA. It has been approved in Europe to treat hemostasis and surgical hemostasis.
Classification
Unknown
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2109072
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
16 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use